Several possible studies
Story checked
A rapid clinical care program increased cancer care access for vulnerable patients (opens in a new tab)
medicalxpress.com · 2026-10-19
Short answer
Several possible studiesNo confirmed study match.
Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
A rapid clinical care program increased cancer care access for vulnerable patients
medicalxpress.com · 2026-10-19
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedThe rapid-access cancer care program Same Day/Next Day (SDND) served a higher proportion of patients with high socioeconomic risk for poor outcomes than the traditional health care path, and more socially vulnerable patients initiated therapy.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedThe study was presented at the 19th AACR Conference on The Science of Cancer Health Disparities in Atlanta.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedSDND connects patients with newly diagnosed or suspected cancer with an oncology nurse practitioner or physician assistant within 48 hours through telehealth appointments.View evidenceHide evidence
As statedwithin 48 hours
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedResearchers compared 1,111 patients evaluated by SDND providers with 1,720 patients seen by the same providers before the program was established, using the Social Vulnerability Index to stratify socioeconomic risk.View evidenceHide evidence
As stated1,111 patients vs 1,720 patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedThe analysis showed that the SDND group had a higher proportion of at-risk patients (21.8%) than the pre-SDND group (15.47%), and a higher proportion of high-risk patients received first-line therapy (17.14% vs 7.09%) in a similar time window of approximately two years.View evidenceHide evidence
As stated21.8% vs 15.47%; 17.14% vs 7.09%; approximately two years
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedThe authors said a key limitation was that the study used population-level data rather than individual patient data, so it did not include stage at presentation, time to treatment, or long-term outcomes.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
Implementation of a Telehealth-Based Rapid Access Program for the Evaluation of Men Referred for Elevated Prostate-Specific Antigen.
Urology Practice · 2026 · PubMed, Europe PMC
Abstract A097: Assessing patterns of cancer screening uptake, healthcare access, health status, and the county-level Social Vulnerability Index in Louisiana
Cancer Epidemiology, Biomarkers & Prevention · 2023 · Crossref
To Screen or Not to Screen: That Is the Question That Can Be Answered Either In-Person or Via Telemedicine-Shared Decision-Making.
2026 · Europe PMC
Utilization of a Third-party Partnership in Tele-genetic Risk Assessment Program in Genitourinary Oncology.
Urology · 2024 · PubMed
Telemedicine Promises Greater Access for Breast Cancer Screening & Treatment
Oncology Times · 2006 · Crossref